{"id":"https://openalex.org/W7204602722","doi":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.377","title":"Pharmaceutical market for bone resorption inhibitors in Uzbekistan: structure, trends, and pricing aspects","display_name":"Pharmaceutical market for bone resorption inhibitors in Uzbekistan: structure, trends, and pricing aspects","publication_year":2026,"publication_date":"2026-08-28","ids":{"openalex":"https://openalex.org/W7204602722","doi":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.377"},"language":"en","primary_location":{"id":"doi:10.17749/2070-4909/farmakoekonomika.2026.377","doi":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.377","is_oa":true,"landing_page_url":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.377","pdf_url":"https://www.pharmacoeconomics.ru/jour/article/download/1467/728","source":{"id":"https://openalex.org/S2764615430","display_name":"FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","issn_l":"2070-4909","issn":["2070-4909","2070-4933"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj","poland-20","russia-white-list-1"],"host_organization":"https://openalex.org/I4210126206","host_organization_name":"Irbis (Czechia)","host_organization_lineage":["https://openalex.org/I4210126206"],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.pharmacoeconomics.ru/jour/article/download/1467/728","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5120461309","display_name":"Ziyodakhon Yusupova","orcid":"https://orcid.org/0009-0002-5198-6511","observed_orcids":["https://orcid.org/0009-0002-5198-6511"]},"institutions":[{"id":"https://openalex.org/I4210096127","display_name":"Tashkent Pharmaceutical Institute","ror":"https://ror.org/00ste1919","country_code":"UZ","type":"education","lineage":["https://openalex.org/I4210096127"]}],"countries":["UZ"],"is_corresponding":false,"raw_author_name":"Z. K. Yusupova","raw_affiliation_strings":["Tashkent Pharmaceutical Institute"],"raw_orcid":"https://orcid.org/0009-0002-5198-6511","affiliations":[{"raw_affiliation_string":"Tashkent Pharmaceutical Institute","institution_ids":["https://openalex.org/I4210096127"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072057266","display_name":"Dilfuza Saipova","orcid":"https://orcid.org/0009-0008-0947-9640","observed_orcids":["https://orcid.org/0009-0008-0947-9640"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. T. Saipova","raw_affiliation_strings":["Educational consulting center Diar Profi"],"raw_orcid":"https://orcid.org/0009-0008-0947-9640","affiliations":[{"raw_affiliation_string":"Educational consulting center Diar Profi","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":15000,"currency":"RUB","value_usd":142},"apc_paid":{"value":15000,"currency":"RUB","value_usd":142},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"19","issue":"3","first_page":"475","last_page":"485"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T14108","display_name":"Medical and Pharmaceutic Studies","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10071","display_name":"Bone health and osteoporosis research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2732","display_name":"Orthopedics and Sports Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antiresorptive-agents","display_name":"antiresorptive agents","score":0.9900000095367432},{"id":"https://openalex.org/keywords/osteoporosis","display_name":"osteoporosis","score":0.9259999990463257},{"id":"https://openalex.org/keywords/pharmaceutical-market","display_name":"pharmaceutical market","score":0.9089999794960022},{"id":"https://openalex.org/keywords/uzbekistan","display_name":"Uzbekistan","score":0.921999990940094},{"id":"https://openalex.org/keywords/zoledronic-acid","display_name":"zoledronic acid","score":0.8460000157356262},{"id":"https://openalex.org/keywords/alendronate","display_name":"alendronate","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.7429999709129333},{"id":"https://openalex.org/keywords/market-concentration","display_name":"market concentration","score":0.8330000042915344},{"id":"https://openalex.org/keywords/generic-drugs","display_name":"generic drugs","score":0.9629999995231628},{"id":"https://openalex.org/keywords/imported-medicines","display_name":"imported drugs","score":0.5139999985694885},{"id":"https://openalex.org/keywords/parenteral-formulations","display_name":"parenteral formulations","score":0.5580000281333923},{"id":"https://openalex.org/keywords/domestic-drug-production","display_name":"domestic drug production","score":0.4729999899864197}],"concepts":[{"id":"https://openalex.org/C2776541429","wikidata":"https://www.wikidata.org/wiki/Q165328","display_name":"Osteoporosis","level":2,"score":0.5996000170707703},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5644000172615051},{"id":"https://openalex.org/C16051113","wikidata":"https://www.wikidata.org/wiki/Q828814","display_name":"Market share","level":2,"score":0.5351999998092651},{"id":"https://openalex.org/C2776326535","wikidata":"https://www.wikidata.org/wiki/Q218507","display_name":"Zoledronic acid","level":2,"score":0.5013999938964844},{"id":"https://openalex.org/C673006","wikidata":"https://www.wikidata.org/wiki/Q4941581","display_name":"Bone resorption","level":2,"score":0.40950000286102295},{"id":"https://openalex.org/C199521495","wikidata":"https://www.wikidata.org/wiki/Q181487","display_name":"Audit","level":2,"score":0.40209999680519104},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3824000060558319},{"id":"https://openalex.org/C2779809032","wikidata":"https://www.wikidata.org/wiki/Q420057","display_name":"Alendronic acid","level":4,"score":0.37389999628067017},{"id":"https://openalex.org/C179036041","wikidata":"https://www.wikidata.org/wiki/Q1901028","display_name":"Market analysis","level":2,"score":0.3677999973297119},{"id":"https://openalex.org/C2777988657","wikidata":"https://www.wikidata.org/wiki/Q66320","display_name":"Over-the-counter","level":3,"score":0.3578999936580658},{"id":"https://openalex.org/C157263771","wikidata":"https://www.wikidata.org/wiki/Q1313706","display_name":"Taxable income","level":2,"score":0.34880000352859497},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.34549999237060547},{"id":"https://openalex.org/C2777251235","wikidata":"https://www.wikidata.org/wiki/Q412205","display_name":"Bisphosphonate","level":3,"score":0.31859999895095825},{"id":"https://openalex.org/C170033053","wikidata":"https://www.wikidata.org/wiki/Q952019","display_name":"Bone remodeling","level":2,"score":0.31769999861717224},{"id":"https://openalex.org/C77281830","wikidata":"https://www.wikidata.org/wiki/Q718608","display_name":"Dosage form","level":2,"score":0.31220000982284546},{"id":"https://openalex.org/C30455989","wikidata":"https://www.wikidata.org/wiki/Q1047494","display_name":"Domestic market","level":2,"score":0.30300000309944153},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.2948000133037567},{"id":"https://openalex.org/C160050368","wikidata":"https://www.wikidata.org/wiki/Q132453","display_name":"Developed country","level":3,"score":0.2915000021457672},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29109999537467957},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.290800005197525},{"id":"https://openalex.org/C3018603563","wikidata":"https://www.wikidata.org/wiki/Q177708","display_name":"Postmenopausal women","level":2,"score":0.2849999964237213},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.27459999918937683},{"id":"https://openalex.org/C2993998788","wikidata":"https://www.wikidata.org/wiki/Q9621","display_name":"Bone structure","level":2,"score":0.27000001072883606},{"id":"https://openalex.org/C138816342","wikidata":"https://www.wikidata.org/wiki/Q189603","display_name":"Public health","level":2,"score":0.267300009727478},{"id":"https://openalex.org/C2994343996","wikidata":"https://www.wikidata.org/wiki/Q2746910","display_name":"International market","level":2,"score":0.2648000121116638},{"id":"https://openalex.org/C2778976249","wikidata":"https://www.wikidata.org/wiki/Q17005820","display_name":"Bone health","level":4,"score":0.25780001282691956},{"id":"https://openalex.org/C146562846","wikidata":"https://www.wikidata.org/wiki/Q96649518","display_name":"Resorption","level":2,"score":0.25619998574256897}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.17749/2070-4909/farmakoekonomika.2026.377","doi":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.377","is_oa":true,"landing_page_url":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.377","pdf_url":"https://www.pharmacoeconomics.ru/jour/article/download/1467/728","source":{"id":"https://openalex.org/S2764615430","display_name":"FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","issn_l":"2070-4909","issn":["2070-4909","2070-4933"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj","poland-20","russia-white-list-1"],"host_organization":"https://openalex.org/I4210126206","host_organization_name":"Irbis (Czechia)","host_organization_lineage":["https://openalex.org/I4210126206"],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.17749/2070-4909/farmakoekonomika.2026.377","doi":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.377","is_oa":true,"landing_page_url":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.377","pdf_url":"https://www.pharmacoeconomics.ru/jour/article/download/1467/728","source":{"id":"https://openalex.org/S2764615430","display_name":"FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","issn_l":"2070-4909","issn":["2070-4909","2070-4933"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj","poland-20","russia-white-list-1"],"host_organization":"https://openalex.org/I4210126206","host_organization_name":"Irbis (Czechia)","host_organization_lineage":["https://openalex.org/I4210126206"],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7204602722.pdf","grobid_xml":"https://content.openalex.org/works/W7204602722.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1834976004","https://openalex.org/W2980406155","https://openalex.org/W2995311105","https://openalex.org/W3042410501","https://openalex.org/W3044260362","https://openalex.org/W3081613390","https://openalex.org/W3196859858","https://openalex.org/W3206749924","https://openalex.org/W4226079456","https://openalex.org/W4280514599","https://openalex.org/W4376626692","https://openalex.org/W4390190767","https://openalex.org/W4406346747","https://openalex.org/W4410069353","https://openalex.org/W4414152521","https://openalex.org/W4415148996","https://openalex.org/W4416274097","https://openalex.org/W4416409708","https://openalex.org/W7172526995"],"related_works":["https://openalex.org/W4416409708","https://openalex.org/W6911089416","https://openalex.org/W2898433687","https://openalex.org/W7172526995","https://openalex.org/W4403035790","https://openalex.org/W4410223363","https://openalex.org/W7221827243","https://openalex.org/W7220316840","https://openalex.org/W7221582978","https://openalex.org/W7138918350"],"abstract_inverted_index":{"Background.":[0],"Osteoporosis":[1],"is":[2],"a":[3,15,49,153,188,230,249],"widespread":[4],"skeletal":[5],"disease":[6],"associated":[7],"with":[8,29,152],"an":[9,148],"increased":[10],"risk":[11],"of":[12,18,24,33,39,55,61,71,79,90,103,106,119,159,200,208,216,224,233,239,263],"fractures":[13],"and":[14,58,74,94,122,141,203,278],"substantial":[16],"burden":[17],"healthcare":[19],"systems.":[20],"The":[21,117,145,236,254],"rising":[22],"prevalence":[23],"osteoporosis":[25],"in":[26,68,100,205,221,251,267],"Uzbekistan,":[27,268],"together":[28],"the":[30,36,46,56,62,69,104,111,165,170,176,184,206,217,222,225,243,257,261],"limited":[31],"number":[32],"studies":[34],"assessing":[35],"pharmaceutical":[37],"market":[38,63,77,146,218,234],"medicines":[40,265],"used":[41],"for":[42,48,64,98,115],"its":[43],"treatment,":[44],"highlights":[45],"need":[47,258],"comprehensive":[50],"marketing":[51],"analysis.":[52],"Objective:":[53],"Analysis":[54],"dynamics":[57],"current":[59],"state":[60],"bone":[65,80],"resorption":[66,81],"inhibitors":[67,82],"Republic":[70,105],"Uzbekistan.":[72],"Material":[73],"methods.":[75],"A":[76,197],"analysis":[78,124],"was":[83,195,219,246],"conducted":[84],"using":[85],"data":[86],"from":[87,190],"State":[88],"Register":[89],"Medicines,":[91],"Medical":[92,95,101],"Devices":[93],"Equipment":[96],"Approved":[97],"Use":[99],"Practice":[102],"Uzbekistan":[107],"as":[108,110],"well":[109],"Drug":[112],"Audit":[113],"database":[114],"2020\u20132025.":[116],"methods":[118],"dynamic,":[120],"comparative,":[121],"structural":[123],"were":[125,211],"applied,":[126],"taking":[127],"into":[128],"account":[129],"dosage":[130,185],"forms,":[131],"international":[132,162],"nonproprietary":[133,163],"names,":[134,136,164],"trade":[135],"manufacturing":[137],"countries,":[138],"sales":[139],"volumes,":[140],"price":[142],"indicators.":[143],"Results.":[144],"demonstrated":[147],"overall":[149],"upward":[150],"trend":[151],"compound":[154],"annual":[155],"growth":[156,172],"rate":[157],"(CAGR)":[158],"+21.30%.":[160],"Among":[161],"zoledronic":[166],"acid":[167,178],"segment":[168,179,223],"showed":[169],"highest":[171],"(CAGR":[173,181],"+55.28%),":[174],"whereas":[175],"alendronic":[177],"declined":[180],"\u201332.35%).":[182],"In":[183],"form":[186],"structure,":[187],"shift":[189],"oral":[191],"to":[192,259,271],"parenteral":[193],"preparations":[194],"observed.":[196],"high":[198,231],"proportion":[199],"imported":[201],"products":[202,241],"fluctuations":[204],"share":[207,238],"domestic":[209,276],"manufacturers":[210],"identified.":[212],"More":[213],"than":[214],"90%":[215],"concentrated":[220],"five":[226],"leading":[227],"drugs,":[228],"indicating":[229],"level":[232],"concentration.":[235],"increasing":[237],"generic":[240],"during":[242],"study":[244],"period":[245],"accompanied":[247],"by":[248],"decrease":[250],"prices.":[252],"Conclusion.":[253],"findings":[255],"substantiate":[256],"diversify":[260],"range":[262],"anti-osteoporotic":[264],"available":[266],"expand":[269],"access":[270],"modern":[272],"therapeutic":[273],"agents,":[274],"promote":[275],"production,":[277],"improve":[279],"pricing":[280],"policies.":[281]},"counts_by_year":[],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2026-08-29T00:00:00"}